[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369411-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369411-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","advanced-organoid-models-for-targeting-kras-driven-lung-adenocarcinoma-in-drug-discovery-and-combination-therapy","Advanced organoid models for targeting Kras-driven lung adenocarcinoma in drug discovery and combination therapy","","Lung cancer remains difficult to treat because of extensive heterogeneity, and KRAS mutations act as key genetic drivers in lung adenocarcinoma. Despite progress in KRAS-targeted therapies, resistance and restricted options require improved preclinical systems. This study develops LUAD organoids from genetically engineered mouse models to enable screening of novel agents and synergistic drug combinations. Tumor-derived organoids reproduce parental tumor features, support in vivo tumorigenicity, and reveal effective kinase and DNMT inhibitor strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/advanced-organoid-models-for-targeting-kras-driven-lung-adenocarcinoma-in-drug-discovery-and-combination-therapy/369411/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/advanced-organoid-models-for-targeting-kras-driven-lung-adenocarcinoma-in-drug-discovery-and-combination-therapy/369411.png","ImageObject",300,407,{"name":42,"@type":43},"Jake","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are advanced preclinical models needed for KRAS-driven lung adenocarcinoma?","Question",{"text":63,"@type":64},"KRAS mutations drive LUAD and, even with KRAS-targeted therapies, treatment resistance and limited therapeutic options persist. Advanced models are needed to screen personalized strategies and synergistic combinations.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the LUAD organoids generated and what did they reproduce?",{"text":68,"@type":64},"LUAD was established in genetically engineered mouse models carrying KrasG12V & Trp53 Δex2−10 (KP) and KP with Ctnnb1Δex3 (KPC). Tumor-derived organoids recapitulated the genomic landscape and histopathological characteristics of the parental tumors.",{"name":70,"@type":61,"acceptedAnswer":71},"Which drug strategy showed the strongest synergy in the organoid models?",{"text":72,"@type":64},"The combination of kinase inhibitors and DNA methyltransferase (DNMT) inhibitors produced the highest synergy in KPC organoids, with effective single-agent activity also observed.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369411,1790830945,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},962084928904,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Taş et al. J Exp Clin Cancer Res (2025) 44:128 [https://doi.org/10.1186/s13046-025-03385-9](https://doi.org/10.1186/s13046-025-03385-9)  \nJournal of Experimental & Clinical Cancer Research  \n RESEARCH Open Access  \nAdvanced organoid models for targeting Kras-driven lung adenocarcinoma in drug discovery and combination therapy  \nİsaTaş1, Ruben Jacobs1, Juliane Albrecht2, Sebastian A. Barrientos 1,4, Josephine Åberg1, Wondossen Sime 1, Hans Brunnström3, Helena Persson2, Julhash U. Kazi 1 and Ramin Massoumi 1*  \nAbstract  \nBackground Lung cancer remains one of the most challenging diseases to treat due to its heterogeneity. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) mutations are genetic drivers in numerous cancer types including lung adenocarcinoma (LUAD) . Despite recent advances in KRAS-targeted therapies, treatment resistance and limited therapeutic options necessitate advanced preclinical models, such as organoids, to identify personalized cancer therapies by screening novel therapeutic strategies and synergistic drug combinations.  \nResults We established LUAD in genetically engineered mouse (GEM) models of KrasG12V & Trp53 Δex2−10 (KP) and KP with Ctnnb1Δex3 mutation (KPC) . Tumor-derived organoids from these models recapitulated the genomic landscape and histopathological characteristics of their parental tumors. The organoids displayed tumorigenic potential when implanted in immunocompromised mice, forming tumors in contrast to unlike healthy lung-derived organoids. Drug screening identified effective kinase inhibitors and DNA methyltransferase (DNMT) inhibitors against the organoids. Notably, the combination of these drugs exhibited the highest synergy in KPC organoids.  \nConclusion We successfully developed LUAD organoids harboring Kras mutations and identified multiple potential therapeutic agents targeting these cells. Furthermore, we demonstrated the effectiveness of a DNMT inhibitor-based combination therapy, presenting a promising strategy for this challenging lung cancer subtype.  \nKeywords Lung adenocarcinoma, Organoids, Kras G12V, Midostaurin, Decitabine  \nIntroduction  \nLung cancer is the leading cause of cancer-related mortality worldwide [1]. Non-small cell lung cancer (NSCLC), accounting for approximately 85% of lung cancer cases,  \n*Correspondence:  \nRamin Massoumi[ramin.massoumi@med.lu.se](ramin.massoumi@med.lu.se)  \n1 Department of Laboratory Medicine, Division of Translational Cancer Research, Lund University, Lund, Sweden  \n2 Department of Clinical Sciences Lund, Division of Oncology, Lund University, Lund, Sweden  \n3 Department of Clinical Sciences Lund, Division of Pathology, Lund University, Lund, Sweden  \n4 IVRS AB, Medicon Village, Scheeletorget 1, 223-81 Lund, SE, Sweden  \nincludes squamous cell carcinoma (SCC) and lung adenocarcinoma (LUAD) as the most common subtypes, accounting for over 40% of all lung tumors [2]. Over the past few decades, substantial progress has been made in understanding the biology and progression mechanisms of lung cancer. With the advent of targeted therapies and immunotherapies, promising clinical outcomes have been achieved. However, despite the advancements in diagnosis and treatment, the prognosis for lung cancer patients remains unsatisfactory [2, 3].  \nKRAS is the most frequently mutated isoform of the RAS family, with approximately 32% of all LUADs being driven by KRAS mutations. The most common types of mutations involve amino-acid substitutions including  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indic","cbCainPJaalnImYh","https://ap.wps.com/l/cbCainPJaalnImYh","pdf",3939586,"English","# Background\n# Results\n## Organoid establishment and characterization\n## Drug screening and combination synergy\n# Conclusion\n# Introduction","[{\"question\":\"Why are advanced preclinical models needed for KRAS-driven lung adenocarcinoma?\",\"answer\":\"KRAS mutations drive LUAD and, even with KRAS-targeted therapies, treatment resistance and limited therapeutic options persist. Advanced models are needed to screen personalized strategies and synergistic combinations.\"},{\"question\":\"How were the LUAD organoids generated and what did they reproduce?\",\"answer\":\"LUAD was established in genetically engineered mouse models carrying KrasG12V \\u0026 Trp53 Δex2−10 (KP) and KP with Ctnnb1Δex3 (KPC). Tumor-derived organoids recapitulated the genomic landscape and histopathological characteristics of the parental tumors.\"},{\"question\":\"Which drug strategy showed the strongest synergy in the organoid models?\",\"answer\":\"The combination of kinase inhibitors and DNA methyltransferase (DNMT) inhibitors produced the highest synergy in KPC organoids, with effective single-agent activity also observed.\"}]","Advanced organoid models for targeting Kras-driven lung adenocarcinoma in drug discovery and combination therapy | PDF",1790182496,48,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0597573287c91d9dd3d8cd4f055f8e73.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ca0889659027e1d229bff41102e08fc9.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/762c23b9a1dec06a46f5fb6fbdb3b4c0.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9163cbec58a7d9d87b617f8d5e8ec0f2.webp",980,1301]